Items where authors include "Duckers, J."

Article

Altaraihi, S., Marthin, J.K., Anagnostopoulou, P. et al. (33 more authors) (2025) International consensus statement on routine blood testing in primary ciliary dyskinesia. ERJ Open Research, 11 (3). 01071-2024. ISSN 2312-0541

Keating, C., Yonker, L.M., Vermeulen, F. et al. (320 more authors) (2025) Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. The Lancet Respiratory Medicine, 13 (3). pp. 256-271. ISSN 2213-2600

Uluer, A.Z., MacGregor, G., Azevedo, P. et al. (103 more authors) (2023) Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. The Lancet Respiratory Medicine, 11 (6). pp. 550-562. ISSN 2213-2600

Acaster, S., Mukuria, C. orcid.org/0000-0003-4318-1481, Rowen, D. orcid.org/0000-0003-3018-5109 et al. (8 more authors) (2023) Development of the CFQ-R-8D: estimating utilities from the cystic fibrosis questionnaire-revised. Value in Health, 26 (4). pp. 567-578. ISSN 1098-3015

Sutharsan, S., McKone, E.F., Downey, D.G. et al. (51 more authors) (2022) Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. The Lancet Respiratory Medicine, 10 (3). pp. 267-277. ISSN 2213-2600